Virtual Library
Start Your Search
qing-yun Gao
Author of
-
+
P87 - Targeted Therapy - Clinically Focused - RET (ID 264)
- Event: WCLC 2020
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P87.05 - RET-Rearranged Squamous Cell Carcinoma of the Lung Responding to First-Line Immunotherapy plus Chemotherapy (ID 3820)
00:00 - 00:00 | Presenting Author(s): qing-yun Gao
- Abstract
Introduction
Few studies have reported whether RET-rearranged patients with lung squamous cell carcinoma respond to first-line immunotherapy plus chemotherapy.
Methods
The clinical data of RET-rearranged patients with advanced non-small cell lung cancer (NSCLC) admitted to the Guangdong Provincial People's Hospital from July 2019 to July 2020 were retrospectively analyzed. RET- rearrangement was detected by next-generation sequencing (NGS). Immunohistochemistry (IHC) showed that the tumor cells were strongly positive for P40 and cytokeratin 5 / 6, but negative for thyroid transcription factor-1.
Results
Among 21 patients with advanced NSCLC with RET rearrangement, the fusion partners were CCDC6 (2 / 21)、 KIF5B (17 / 21)、TRM24 (1 / 21) andKIF5B /PRKG1(1 / 21). Seventeen cases were diagnosed with lung adenocarcinoma, 2 were lung adenosquamous carcinoma, 1 was lung squamous cell carcinoma, and 1 was unknown. Twelve cases received first-line chemotherapy, 3 receiving first-line targeted therapy, and 5 had unknown first-line treatment history. The only one case oflung squamous cell carcinoma was treated withfirst-line immunotherapy plus chemotherapy. She had no history of smoking and family history of malignancy. After CT-guided lung biopsy, immunohistochemistry (IHC) analysis showed that P40 and cytokeratin 5 / 6 were strongly positive, ALK (D5F3) and thyroid transcription factor-1 were negative, PD-L1 (22C3) (TPS, 15% +). It was a typical squamous cell carcinoma of the lung. NGS of both tumor tissue and plasm showed KIF5B- RET rearrangement (K15: R12) and TP53p.y236c mutation. After 6 cycles of pembrolizumab plus nab-paclitaxel/carbpplatin, the best response was PR. The progression-free survival was 5 months.
Conclusion
RET- rearranged lung squamous cell carcinoma was rare in advanced NSCLC. However, objective response to first-line immunotherapy plus chemotherapy could be achieved in such tumors.
